ZN-c3

SKU: orb1297962

Description

Azenosertib (ZN-c3) is a selective and potent small molecule inhibitor of the Wee1 kinase. It is utilized in cancer research, particularly in studying DNA damage response and cell cycle checkpoint override, with demonstrated activity in both in vitro and in vivo preclinical models.

Research Area

Cell Biology

Key Properties

• CAS Number: 2376146-48-2
• MW: 526.63
• Purity: 99.98% (May vary between batches)
• Formula: C₂₉H₃₄N₈O₂
• SMILES: C(C=C)N1N(C=2C(C1=O)=CN=C(NC3=CC=C(C=C3)N4CCN(C)CC4)N2)C=5N=C6C(=CC5)CC[C@@]6(CC)O
• Target: Wee1
• Solubility: DMSO:50 mg/mL (94.94 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (9.49 mM)

Bioactivity

• In Vivo:
  The pharmacokinetic data of Azenosertib (10 mg/kg, oral) showed that the plasma exposure rate of Azenosertib in the beagle dog model was Cmax = 2.1 μM, the half-life T1/2 was 2.3 h, the AUC0-24 h was 9.7 μM·h, and the oral availability was F=142%; Azenosertib (80 mg/kg, oral for 28 days) inhibited the tumor growth of A427 xenograft tumors in the NOD/SCID mouse model
  Read more...
• In Vitro:
  METHODS: Azenosertib (ZN-c3) was used to treat cancer cells H23 for three days and A427 for four days, and the proliferation of cancer cells was observed. RESULTS Azenosertib (ZN-c3) inhibited the proliferation of cancer cells H23 and A427, with IC50 of 103 and 75 nM.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Wee1, ZNc3, ZN-c3, ZN c3

Compound Identifiers

PubChem CID

139467635